Bayer and Onyx’s Cancer Drug Approved by FDA

Bayer and Onyx Pharmaceuticals have announced that US regulators have approved Stivarga for the treatment of metastatic colorectal cancer. Yesterday, the Food and Drug Administration (FDA) approved Stivarga (regorafenib) for the medication of patients with mCRC who have been previously been treated with currently available therapies. The green light for the oral multi-kinase inhibitor is

Continue Reading

Bayer To Submit Regorafenib After Positive Survival Statistics

Bayer has provided more information about their recently-halted late-stage trial of their colorectal cancer drug, regorafenib, which shows that the drug improved overall survival by 29%, meeting its primary endpoint. In October, the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial, which contained 760 patients with metastatic

Continue Reading